希罗达联合多西他赛治疗转移性乳腺癌36例临床观察

目的：观察希罗达联合多西他赛治疗蒽环类失败复发转移性乳腺癌的临床疗效和毒副反应。方法：希罗达单药2500mg／（m^2·d），分早晚2次，餐后30min内口服。连续服用2周，休息1周为1个周期。多西他赛使用前1天口服地塞米松8mg，2次／天，连用3天。多西他赛75rag／m^2，静脉滴注1h，d1，每21天为1周期。至少应用2周期后评价疗效。每周期化疗前后复查血常规及生化指标。结果：全部36例可评价疗效，平均化疗4个周期后完全缓解（ca）0例，部分缓解（PR）14例，占38．9％，稳定（SD）16例，占44．4％，进展（PD）6例占16．7％，客观有效率（ORR）83．3％（30／36）。最常见的毒副反应为手足综合征、腹泻、厌食、恶心、腹胀、头昏、口腔炎，而中性粒细胞减少相对较少。结论：希罗达联合多西他赛治疗使用蒽环类失败复发转移性乳腺癌疗效确切，毒副反应可耐受。

Clinical observation of 36 cases with metastatic breast cancer treated by xeloda combining with with docetaxel

Objective：To observe the clinical efficacy and toxic side effects of xeloda combined with docetaxel in the treatment for patients with anthracycline -resistant metastatic breast cancer. Methods： All patients were injected docecaxel （75 mg/m^2） intravenously for 1 hour in the first day before which dexamethasone（8mg） was taken orally two times a day for three days, and 1 cycle was 21 days. All patients were taken orally xeloda 2500 mg （ m^2· d） after 30 min of Meal, which was divided into sooner or later two time for 2 weeks, successive application for two weeks and rested 1 week, which called 1 sycle. Evaluation were perfomed after 2 cycles. Blood routine and biochemical indexes were rechecked before and after chemotherapy each cycle. Results： All patients evaluated the response after on average four cycles in which complete response（CR） was 0（0%） case, partial response（PR） 14（38.9%） cases, stable discase（SD） 6（16.7%） cases, objective response rate 30/36（83.3%）. The major toxic side effects was hand -foot syndrome, diarrhea, anorexia, nausea, abdominal distension, dizziness, stomatitis; and serious granulocytoponia was uncommon. Condusion： Docetaxel combind with xeloda is active for the patients with anthracycline - resistant metastatic breast canccr, and toxic side effects is acceptably tolerant.